Superdrol is an oral synthetic steroid related to testosterone, never approved as a medicine, valued for a reputation of fast muscle and strength gains. No controlled human study of it exists; expected gains are borrowed from related steroids. The harm record is more specific to the compound: severe blocked bile flow with yellowing skin, sometimes kidney failure, often after the last dose. Serious downsides stand against unmeasured benefits. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Total and direct bilirubin | Total 0.1–1.2 mg/dL | Earliest sign of blocked bile flow; stop trigger |
| ALT and AST | At or below laboratory upper limit of normal | Liver injury; stop trigger |
| ALP and GGT | At or below laboratory upper limit of normal | Bile-duct markers; ALP is a stop trigger |
| Creatinine | Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL | Kidney injury accompanying blocked bile flow |
| HDL and LDL cholesterol | No established target; change from own baseline | HDL falls on oral steroids |
| Total testosterone, LH, FSH | Total testosterone 264–916 ng/dL in men | Suppressed during use; tracks recovery afterward |
| Complete blood count | Hemoglobin 13.2–16.6 g/dL in men; platelets 150–450 ×10⁹/L | Raised hematocrit (clot risk); rare marrow failure after liver injury |
| Lean mass by DXA scan | No established target; change from own baseline | Lean mass rises during use |
| Blood pressure | Baseline reading as personal reference point | Part of baseline testing before any exposure |
Cadence: Baseline within 2 weeks before any exposure; liver tests and creatinine at weeks 2 and 4 of a course, then 2, 4 and 12 weeks after the last dose; lipids at week 4; testosterone, LH and FSH 8–12 weeks after stopping